Aligos Therapeutics Financials - Benzinga

Aligos Therapeutics Inc

ALGSNASDAQ

Trade with Public

Trade with Public

$6.89

0.121.77%

At close: Aug 14, 5:00 PM EST

$6.89

N/A

After Hours: Aug 14, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Aligos Therapeutics Financials

Aligos Therapeutics (ALGS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share

Benzinga Newsdesk

PRO
Aligos Therapeutics Q1 EPS $(2.21) Beats $(2.28) Estimate, Sales $2.830M Beat $500.000K Estimate

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the analyst consensus estimate of $(2.28) by 3.07 percent. This is a 4.74 percent decrease over losses of $(2.11) per share from

Benzinga Newsdesk

Aligos Therapeutics Earnings Report: Q4 Overview

Benzinga Insights

PRO
Aligos Therapeutics Q4 EPS $(1.91) Beats $(2.27) Estimate, Sales $169.000K Miss $800.000K Estimate.

Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.27) by 15.67 percent. This is a 85.4 percent increase over losses of $(13.08) per share

Benzinga Newsdesk

Earnings Scheduled For March 5, 2026

Benzinga Insights

A Peek at Aligos Therapeutics's Future Earnings

Benzinga Insights